Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 9/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101779 | 1.00 | PTGES (0.46) | PTGESLRRK2PDE4BRAF1DYRK1A | |
| SCHEMBL3093989 | 0.88 | PTGES (0.46) | PTGESLRRK2PDE4BRAF1 | |
| SCHEMBL3226029 | 0.88 | PTGES (0.46) | PTGESLRRK2PDE4B | |
| SCHEMBL3226021 | 0.88 | PTGES (0.46) | PTGESLRRK2PDE4B | |
| SCHEMBL3101915 | 0.88 | PTGES (0.47) | PTGESLRRK2RAF1 | |
| SCHEMBL3101042 | 0.88 | PTGES (0.45) | PTGESLRRK2PDE4B | |
| SCHEMBL3101035 | 0.88 | PTGES (0.45) | PTGESLRRK2PDE4B | |
| SCHEMBL3101832 | 0.83 | PTGES (0.45) | PTGESLRRK2RAF1 | |
| SCHEMBL3109624 | 0.81 | PTGES (0.67) | PTGES | |
| SCHEMBL3109637 | 0.81 | PTGES (0.67) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196897-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885LRRK2 3446/4885PDE4B 849/4885 |
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885LRRK2 3446/4885PDE4B 849/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885LRRK2 3446/4885PDE4B 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.